There is controversy over whether therapy to prevent ventricular tachyarrhythmias should be selected noninvasively (by trying drugs and monitoring the patient electrocardiographically) or invasively (by selecting a drug that prevents induction of the arrhythmia by programmed stimulation). We randomly assigned 57 patients with symptomatic and demonstrable ventricular tachyarrhythmias to therapy selected either noninvasively or invasively. The tachyarrhythmias involved were sustained ventricular tachycardia (35 patients), nonsustained ventricular tachycardia with hypotension (15 patients), and ventricular fibrillation (7 patients). The noninvasive approach sought reduction of ventricular premature beats by more than 80 percent and of couplets by more than 90 percent, with elimination of three or more successive ventricular beats on ambulatory monitoring and exercise testing. The invasive approach sought to prevent the induction of five or more repetitive beats by programmed stimulation. The noninvasive approach required fewer drug trials (3.2 +/- 1.8 [mean +/- SD] vs. 5.5 +/- 2.8, P less than 0.001) and fewer hospital days (20 +/- 15 vs. 33 +/- 24, P = 0.01) and identified a therapy predicted to be effective for more patients than did the invasive approach (29 of 29 vs. 15 of 28, P less than 0.001). When a predicted effective therapy was not found, amiodarone was prescribed despite persisting inducibility of ventricular tachycardia. Patients randomly assigned to the noninvasive approach had more symptomatic recurrences of tachyarrhythmia than those treated by the invasive approach (two-year actuarial probabilities of 0.50 +/- 0.10 vs. 0.20 +/- 0.08, P = 0.02). Similar differences were observed when amiodarone recipients were excluded. There were only three deaths from recurrent ventricular tachyarrhythmias--two in the group whose treatment was selected noninvasively and one in the group whose treatment was selected invasively (not significant). We conclude that therapy selected by the invasive approach prevents recurrences of ventricular tachyarrhythmias better than that selected by the noninvasive approach.
Source Information
Department of Medicine, Foothills General Hospital, Calgary, Alta., Canada.
This article has been cited by other articles:
Cappato, R., Boczor, S., Kuck, K.-H., on behalf of the CASH Investigators,
(2004). Response to programmed ventricular stimulation and clinical outcome in cardiac arrest survivors receiving randomised assignment to implantable cardioverter defibrillator or antiarrhythmic drug therapy. Eur Heart J
25: 642-649
[Abstract][Full Text]
Kadish, A. H., Buxton, A. E., Kennedy, H. L., Knight, B. P., Mason, J. W., Schuger, C. D., Tracy, C. M., Winters, W. L. Jr, Boone, A. W., Elnicki, M., Hirshfeld, J. W. Jr, Lorell, B. H., Rodgers, G. P., Tracy, C. M., Weitz, H. H.
(2001). ACC/AHA Clinical Competence Statement on Electrocardiography and Ambulatory Electrocardiography: A Report of the ACC/AHA/ACP-ASIM Task Force on Clinical Competence (ACC/AHA Committee to Develop a Clinical Competence Statement on Electrocardiography and Ambulatory Electrocardiography) Endorsed by the International Society for Holter and Noninvasive Electrocardiology. Circulation
104: 3169-3178
[Full Text]
Kadish, A. H., Buxton, A. E., Kennedy, H. L., Knight, B. P., Mason, J. W., Schuger, C. D., Tracy, C. M., Winters, W. L. Jr, Boone, A. W., Elnicki, M., Hirshfeld, J. W. Jr, Lorell, B. H., Rodgers, G. P., Tracy, C. M., Weitz, H. H.
(2001). ACC/AHA clinical competence statement on electrocardiography and ambulatory electrocardiography: A report of the ACC/AHA/ACP-ASIM Task Force on Clinical Competence (ACC/AHA Committee to Develop a Clinical Competence Statement on Electrocardiography and Ambulatory Electrocardiography) Endorsed by the International Society for Holter and Noninvasive Electrocardiology. J Am Coll Cardiol
38: 2091-2100
[Full Text]
Wyse, D. G., Talajic, M., Hafley, G. E., Buxton, A. E., Mitchell, L. B., Kus, T. K., Packer, D. L., Kou, W. H., Lemery, R., Santucci, P., Grimes, D., Hickey, K., Stevens, C., Singh, S. N., for the MUSTT Investigators,
(2001). Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT): drug testing and as-treated analysis. J Am Coll Cardiol
38: 344-351
[Abstract][Full Text]
Lazzara, R.
(2001). Will Antiarrhythmic Drug Therapy Guided by Electrophysiology Study Survive in the New Millennium?. J CARDIOVASC PHARMACOL THER
6: 1-4
Welch, P. J., Page, R. L., Hamdan, M. H.
(1999). Management of ventricular arrhythmias: A trial-based approach. J Am Coll Cardiol
34: 621-630
[Abstract][Full Text]
Crawford, M. H., Bernstein, S. J., Deedwania, P. C., DiMarco, J. P., Ferrick, K. J., Garson, A. Jr, Green, L. A., Greene, H. L., Silka, M. J., Stone, P. H., Tracy, C. M., Gibbons, R. J., Alpert, J. S., Eagle, K. A., Gardner, T. J., Garson, A. Jr, Gregoratos, G., Russell, R. O., Ryan, T. J., Smith, S. C. Jr
(1999). ACC/AHA guidelines for ambulatory electrocardiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography) developed in collaboration with the North American Society for Pacing and Electrophysiology. J Am Coll Cardiol
34: 912-948
[Full Text]
Goldberger, J. J.
(1999). Treatment and Prevention of Sudden Cardiac Death: Effect of Recent Clinical Trials. Arch Intern Med
159: 1281-1287
[Abstract][Full Text]
Cannom, D. S., Prystowsky, E. N.
(1999). Management of Ventricular Arrhythmias: Detection, Drugs, and Devices. JAMA
281: 172-179
[Abstract][Full Text]
Sharma, P. P., Ott, P., Hartz, V., Mason, J. W., Marcus, F. I.
(1998). Risk Factors for Tachycardia Events Caused by Antiarrhythmic Drugs: Experience From the ESVEM Trial. J CARDIOVASC PHARMACOL THER
3: 269-274
[Abstract]
Reiffel, J. A.
(1996). Data-driven Decisions: The Importance of Clinical Trials in Arrhythmia Management. J CARDIOVASC PHARMACOL THER
1: 79-88
[Abstract]
Sheldon, R., Duff, H., Koshman, M. L.
(1995). Antiarrhythmic Activity of Quinine in Humans. Circulation
92: 2944-2950
[Abstract][Full Text]
Hubley-Kozey, C. L., Mitchell, L. B., Gardner, M. J., Warren, J. W., Penney, C. J., Smith, E. R., Horacek, B. M.
(1995). Spatial Features in Body-Surface Potential Maps Can Identify Patients With a History of Sustained Ventricular Tachycardia. Circulation
92: 1825-1838
[Abstract][Full Text]
Reiter, M. J., Mann, D. E., Reiffel, J. E., Hahn, E., Hartz, V.
(1995). Significance and Incidence of Concordance of Drug Efficacy Predictions by Holter Monitoring and Electrophysiological Study in the ESVEM Trial. Circulation
91: 1988-1995
[Abstract][Full Text]
Omoigui, N. A., Marcus, F. I., Mason, J. W., Hahn, E. A., Hartz, V. L., Hlatky, M. A.
(1995). Cost of Initial Therapy in the Electrophysiological Study Versus ECG Monitoring Trial (ESVEM). Circulation
91: 1070-1076
[Abstract][Full Text]
Mason, J. W., The Electrophysiologic Study versus Electrocardiog,
(1993). A Comparison of Electrophysiologic Testing with Holter Monitoring to Predict Antiarrhythmic-Drug Efficacy for Ventricular Tachyarrhythmias. NEJM
329: 445-451
[Abstract][Full Text]
Ward, D. E., Camm, A. J.
(1993). Dangerous Ventricular Arrhythmias -- Can We Predict Drug Efficacy?. NEJM
329: 498-499
[Full Text]
McCollam, P. L., Bauman, J. L.
(1989). New Concepts in Antiarrhythmic Drug Monitoring. Journal of Pharmacy Practice
2: 393-402
(1988). INVASIVE VERSUS NONINVASIVE TESTING OF ANTIARRHYTHMICS. JWatch General
1988: 4-4
[Full Text]
